SF and Silicon Valley: Drop the Incrementalism and Invest in True Innovation

spend more time engaging with regional experts in their field of choice to understand what kinds of research will lead to true, game-changing advances.

For venture capitalists, this means backing ideas that may be more long-term (sometimes beyond the typical 3-5 year time horizon) and risky, supporting business models that may (at first) be unclear. This may go against the conventional way of how to solve a problem, but it nevertheless promises to provide a much larger payoff that will deliver the kinds of returns that the venture capital asset class needs in order to be viable. This also means that VC investors must be more patient and must be more willing to stick out their necks to back opportunities outside of what their peers seem to gravitate to (imagine that-venture capitalists that actually invest creatively!).

As I look at our own investment portfolio as an example of this investing approach, I note that our successes have come largely from seeding ideas that represent truly innovative approaches to solving unmet needs. This has been the case with our own investments in IT, like Farecast, which was acquired by Microsoft for developing an innovative airfare prediction technology. It happened in life sciences with Alder Biopharmaceuticals, which  secured a $1B+ partnership with Bristol-Myers Squibb to advance therapeutics derived from a platform for uniquely identifying, developing, and manufacturing novel antibody therapeutics in the autoimmune and inflammatory disease areas. It’s happening in energy as well, with EnerG2, which has secured significant federal stimulus funding to commercially develop and manufacture high-performance, nano-engineered synthetic carbon electrode materials for ultracapacitor energy storage devices.

Get Big Companies Involved Sooner: Entrepreneurs and VCs need to approach potential corporate partners much earlier as they seek to solve problems with innovative approaches. Many large corporations are recognizing the need to invest in innovation at an earlier stage. Witness recent activities by companies like Apple, General Motors, Google, SAP, T-Mobile, and numerous others in the last couple of years who have set up meaningful investment vehicles to help financially back innovative startup companies in their respective fields. Corporate cultures are shifting to be much more supportive of spinning out technologies that may be non-core to the larger company’s current area of focus. Public shareholders, like venture capital investors, are demanding more focus from larger companies in their ongoing quest to maximize shareholder value.

Investors and entrepreneurs should use this as an opportunity to develop new, early-stage companies that will take the best, most innovative technologies forward. Research compiled by the National Venture Capital Association, Thomson Reuters, and others have pointed out that venture capital investor exits today are coming more from trade sales (M&A) than from initial public offerings. So it would seem to be prudent to stay close to potential buyers to figure out what they plan to buy, and to craft your startup development strategy with this information in mind.

Diversify Risk within Early-Stage Companies: Finally, VCs and entrepreneurs can maximize the potential for a successful outcome and a much smoother ride by diversifying risk within their respective companies. This means encouraging a reasonable diversification mindset, where entrepreneurs (supported by their VCs) would consider developing their core technologies to address peripheral markets. In some cases, these peripheral markets may be smaller in size or overall potential, or may be an unanticipated use of a core technology originally developed for one market but effective for use in another market. Using this kind of mindset effectively has helped us at WRF Capital in managing product development risk within our own investment portfolio, and in some cases has enabled our companies to significantly extend their financial runways by obtaining valuable, non-dilutive sources of funding (either from customers, government or non-profit institution grants, or other strategic investors). This is particularly important given the current economic climate where raising new outside capital can be challenging even for the best companies.

There’s no question that San Francisco and Silicon Valley continue to be well-positioned to make significant contributions to the 21st century economy. If VCs and entrepreneurs are willing to take this advice to heart, they will be even better positioned to ride out any ups and downs that the markets have to dish out.

Author: Thong Le

Thong Q. Le serves as Chief Executive Officer (CEO) of Accelerator Corporation. With more than 16 years of experience in identifying, investing, managing, and successfully exiting numerous seed and early-stage investments, Mr. Le is positioned to grow and expand the Accelerator investment model. He currently serves as CEO and Director of Acylin Therapeutics and Oncofactor Corporation, and is a Board Observer at AnswerDash and Cardeas Pharma. Prior to becoming CEO at Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation in Seattle, WA. During his 13-year tenure at WRF Capital, Mr. Le played a significant role in the early sourcing, financing, and development of numerous start-up companies, including Alder Biopharmaceuticals (NASDAQ: ALDR), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO.L), Hyperion Therapeutics (Nasdaq: HPTX), Lumera (NasdaqNM: LMRA), Performant (acquired by Mercury Interactive), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). He also led WRF Capital’s investments in Accelerator, AnswerDash, ARZEDA, Cardeas Pharma, Resolve Therapeutics, and Uptake Medical, all companies where he was actively involved in establishing as a founding or early investor. Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures. Mr. Le completed post-graduate studies at the Templeton College of Oxford University and earned a bachelor of arts cum laude in government from Harvard University. He currently serves on the executive boards of the Evergreen Venture Capital Association (EVCA), the Washington Biotechnology & Biomedical Association, and the Washington Global Health Fund. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal.